Fibrinogen contains cryptic PAI-1 binding sites that are exposed on binding to solid surfaces or limited proteolysis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 12, 2005, Pages 2679-2684

  Smolarczyk, Katarzyna ^a   Boncela, Joanna ^a   Szymanski, Jacek ^b   Gils, Ann ^c   Cierniewski, Czeslaw S ^a,b  

^a POLISH ACADEMY OF SCIENCES   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Conformational changes; Fibrinogen; PAI 1 binding sites; Proteolysis

Indexed keywords

FIBRIN; FIBRINOGEN; FIBRINOPEPTIDE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEIN; THROMBIN; FIBRINOGEN AALPHA; PEPTIDE FRAGMENT; PLASMIN; VITRONECTIN;

ADSORPTION; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CELL MIGRATION; EXPOSURE; INFLAMMATION; INJURY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; SOLID; SURFACE PLASMON RESONANCE; SURFACE PROPERTY; TWO HYBRID SYSTEM; WOUND HEALING; CHEMISTRY; GENE LIBRARY; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; THROMBOSIS;

ADSORPTION; BINDING SITES; FIBRIN; FIBRINOGEN; GENE LIBRARY; HUMANS; PEPTIDE FRAGMENTS; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN STRUCTURE, TERTIARY; SURFACE PLASMON RESONANCE; THROMBOSIS; TWO-HYBRID SYSTEM TECHNIQUES; VITRONECTIN;

EID: 33644795179     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000189305.84297.8b     Document Type: Article

References (30)

1. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geogheggan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature. 1992;355:270-273.
2. Lawrence DA, Olson ST, Palaniappani S, Ginsburg D. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability. Biochemistry. 1994;33:3643-3648.
3. Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, Muller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem. 1988;263:15454-15461.
4. Salonen EM, Vaheri A, Pollanen J, Stephen R, Andreasen P, Mayer M, Gailit J, Ruoslahti E. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem. 1989;264:6339-6343.
5. Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol. 2003;10:541-544.
6. 1acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity. J Biol Chem. 2001;276:35305-35311.
7. Horrevoets AJ. Plasminogen activator inhibitor 1 (PAI-1): in vitro activities and clinical relevance. Br J Haematol. 2004;125:12-23.
8. Stringer HA, Pannekoek H. The significance of fibrin binding by plasminogen activator inhibitor 1 for the mechanism of tissue-type plasminogen activator-mediated fibrinolysis. J Biol Chem. 1995;270:11205-11208.
9. Reilly CF, Hutzelmann JE. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution. J Biol Chem. 1992;267:17128-17135.
10. Wagner O, de Vries C, Hohmann C, Veerman H, Pannekoek H. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. J Clin Invest. 1989;84:647-655.
11. Reilly C, Fujita T, Hutzelmann J, Mayer E, Shebuski R. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism. Circulation. 1991;84:287-292.
12. Seiffert D, Schleef RR. Two functionally distinct pools of vitronectin (Vn) in the blood circulation: identification of a heparin-binding competent population of Vn within platelet alpha-granules. Blood. 1996;88:552-560.
13. Podor TJ, Peterson CB, Lawrence DA, Stefansson S, Shaughnessy SG, Foulon DM, Butcher M, Weitz JI. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. J Biol Chem. 2000;275:19788-19794.
14. Stringer HAR, van Swieten P, Hejinen HVG, Sixma JJ, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop. Arterioscler Thromb. 1994;14:1452-1458.
15. Torr-Brown SR, Sobel BE. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res. 1993;72:413-421.
16. Degryse B, Neels JG, Czekay RP, Aertgeerts K, Kamikubo Y, Loskutoff DJ. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chew. 2004;279:22595-22604.
17. Chapman HA, and Wei Y. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb Haemost. 2001;86:124-129.
18. Sidenius N, and Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 2003;22:205-222.
19. Pawlowska Z, Baranska P, Jerczynska H, Koziolkiewicz W, Cierniewski CS. Heat shock proteins and other components of cellular machinery for protein synthesis are up-regulated in vascular endothelial cell growth factor-activated human endothelial cells. Proteomics. 2005;5:1217-1227.
20. Cierniewski CS, Swiatkowska M, Poniatowski J, Niewiarowska J. Anti-(Arg-Gly-Asp-Ser) antibody and its interaction with fibronectin, fibrinogen and platelets. Eur J Biochem. 1988;177:109-115.
21. Gils A, Alessi MC, Brouwers E, Peeters M, Marx P, Leurs J, Bouma B, Hendriks D, Juhan-Vague I, Declerck PJ. Development of a genotype 325-specific proCPU/TAFI enzyme-linked immunosorbent assay. Arterioscler Thromb Vasc Biol. 2003;23:1122-1127.
22. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150:76-85.
23. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
24. Lawrence DA, Berkenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem. 1994;269:15223-15228.
25. Michelsen ME, Santi C, Holme R, Lord ST, Simpson-Haidaris PJ, Solum NO, Pedersen TM, Brosstad F. The charge-heterogeneity of human fibrinogen as investigated by 2D electrophoresis. Thromb Res. 2000;100:529-535.
26. Arroyo De Prada N, Schroeck F, Sinner EK, Muehlenweg B, Twellmeyer J, Sperl S, Wilhelm OG, Schmitt M, Magdolen V. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin. Eur J Biochem. 2002;269:184-192.
27. Pechik I, Madrazo J, Mosesson MW, Hernandez I, Gilliland GL, Medved L. Crystal structure of the complex between thrombin and the central "E" region of fibrin. Proc Natl Acad Sci U S A. 2004;101:2718-2723.
28. Walker JB, Nesheim ME. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem. 1999;274:5201-5212.
29. Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. (2004) Blood. 2004;104:3943-3948.
30. Simpson AJ, Booth NA, Moore NR, Bennett B. The platelet and plasma pools of plasminogen activator inhibitor (PAI-1) vary independently in disease. Br J Haematol. 1990;75:543-548.